Patricia Verduin
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
FMC completes minority stake with Tessenderlo, sets Q3 earnings date. FMC Corporation and Tessenderlo Group have completed a minority equity investment, adding a new strategic partner to the business. The company also announced the date for its third‑quarter 2026 earnings release and the accompanying webcast. Recent commentary noted that the stock has fallen sharply, making it appear inexpensive relative to sales, a point that may be of interest given its current price near a long‑standing support level.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target. Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Colgate-Palmolive dividend focus ahead of Q3 earnings call. Recent coverage lists Colgate‑Palmolive as a dividend champion and a contender for income‑focused investors. The company will host its 2026 third‑quarter earnings webcast on October 30, where results and guidance are expected. Investors noting the upcoming November 13 dividend should be aware of the October 20 record date to qualify for the payment. The stock continues to trade with a dividend yield of about 2.5%.
Transaction History
| AVNT | ▲ Buy | Grant | 958 | $0 | 9/30/2026 | View on chart |
| FMC | ▲ Buy | Grant | 50 | $0 | 7/16/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,049 | $0 | 6/30/2026 | View on chart |
| INGR | ▲ Buy | Grant | 1,797 | $193K | 5/20/2026 | View on chart |
| FMC | ▲ Buy | Grant | 9,175 | $0 | 4/28/2026 | View on chart |
| FMC | ▲ Buy | Grant | 18 | $0 | 4/16/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,072 | $0 | 3/31/2026 | View on chart |
| INGR | ▲ Buy | Grant | 380 | $43K | 3/31/2026 | View on chart |
| FMC | ▲ Buy | Grant | 22 | $0 | 1/15/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,239 | $0 | 12/31/2025 | View on chart |
| INGR | ▲ Buy | Grant | 371 | $40K | 12/5/2025 | View on chart |
| FMC | ▲ Buy | Grant | 63 | $0 | 10/16/2025 | View on chart |
| INGR | ▲ Buy | Grant | 321 | $40K | 9/30/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,192 | $0 | 9/30/2025 | View on chart |
| FMC | ▲ Buy | Grant | 50 | $0 | 7/17/2025 | View on chart |
| INGR | ▲ Buy | Grant | 290 | $40K | 6/30/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,187 | $0 | 6/30/2025 | View on chart |
| FMC | ▲ Buy | Grant | 3,355 | $0 | 4/29/2025 | View on chart |
| FMC | ▲ Buy | Grant | 17 | $0 | 4/17/2025 | View on chart |
| INGR | ▲ Buy | Grant | 301 | $40K | 3/31/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,055 | $0 | 3/31/2025 | View on chart |
| FMC | ▲ Buy | Grant | 15 | $0 | 1/16/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 955 | $0 | 12/31/2024 | View on chart |
| INGR | ▲ Buy | Grant | 274 | $40K | 12/12/2024 | View on chart |
| FMC | ▲ Buy | Grant | 11 | $0 | 10/17/2024 | View on chart |
| INGR | ▲ Buy | Grant | 295 | $40K | 9/30/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 775 | $0 | 9/30/2024 | View on chart |
| FMC | ▲ Buy | Grant | 12 | $0 | 7/18/2024 | View on chart |
| INGR | ▲ Buy | Grant | 346 | $40K | 6/28/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 806 | $0 | 6/28/2024 | View on chart |
| FMC | ▲ Buy | Grant | 2,373 | $0 | 4/30/2024 | View on chart |
| INGR | ▲ Buy | Grant | 342 | $40K | 3/29/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 808 | $0 | 3/29/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 834 | $0 | 12/29/2023 | View on chart |
| INGR | ▲ Buy | Grant | 360 | $37K | 12/11/2023 | View on chart |
| INGR | ▲ Buy | Grant | 376 | $37K | 9/29/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 984 | $0 | 9/29/2023 | View on chart |
| FMC | ▲ Buy | Grant | 1,158 | $0 | 7/17/2023 | View on chart |
| INGR | ▲ Buy | Grant | 167 | $18K | 6/30/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 863 | $0 | 6/30/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 857 | $0 | 3/31/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 1,040 | $0 | 12/31/2022 | View on chart |
| CL | ▼ Sell | Other | 1,610 | $118K | 11/7/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 1,139 | $0 | 9/30/2022 | View on chart |
| CL | ▲ Buy | Option Exercise | 49,069 | $3.6M | 8/5/2022 | View on chart |
| CL | ▼ Sell | Open Market | 49,069 | $3.9M | 8/5/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 880 | $0 | 6/30/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 717 | $0 | 3/31/2022 | View on chart |
| CL | ▼ Sell | Open Market | 6,306 | $500K | 2/18/2022 | View on chart |
| CL | ▲ Buy | Grant | 12,450 | $0 | 2/17/2022 | View on chart |
| CL | ▲ Buy | Option Exercise | 51,194 | $3.7M | 2/2/2022 | View on chart |
| CL | ▼ Sell | Open Market | 51,194 | $4.2M | 2/2/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 627 | $0 | 12/31/2021 | View on chart |
| CL | ▼ Sell | Tax Withholding | 205 | $16K | 12/8/2021 | View on chart |
| AVNT | ▲ Buy | Grant | 744 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Avient Announces New CEO Mike Frank, Reaffirms Guidance
Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.
Avient Announces New CEO Mike Frank, Reaffirms Guidance. Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.